DIQTA 1.0: Drug-Induced QT Prolongation Atlas

LEVALBUTEROL TARTRATE

Classification:Ambiguous

Severity Score:1.0

WARNINGS AND PRECAUTIONS
Cardiovascular Effects
XOPENEX HFA, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and symptoms. Although such effects are uncommon after administration of XOPENEX HFA at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T-wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, XOPENEX HFA, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Current Drug

Other Drugs

QT Prolongation

24089

Other ADRs

3005

38378582

Odds Ratio = 1.591

ATC Code(s):

Active Ingredient:levalbuterol tartrate

Active Ingredient UNII:ADS4I3E22M

Drugbank ID:DB13139

PubChem Compound:123600

CTD ID:D064412

PharmGKB:

CAS Number:34391-04-3

Dosage Form(s):aerosol, metered

Route(s) Of Administrator:oral

Daily Dose:

Chemical Structure:

SMILE Code:
CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1

N/A